These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29299639)

  • 1. B7-H3 in tumors: friend or foe for tumor immunity?
    Li G; Quan Y; Che F; Wang L
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
    Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
    Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3-mediated tumor immunology: Friend or foe?
    Wang L; Kang FB; Shan BE
    Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
    Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
    Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.
    Hashiguchi M; Kobori H; Ritprajak P; Kamimura Y; Kozono H; Azuma M
    Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10495-500. PubMed ID: 18650384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research Progress on Co-stimulating Molecule B7-H3 in Hematological Malignancies].
    Zhang W; Wang J; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1758-62. PubMed ID: 26708906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine b7-h3 is a co-stimulatory molecule for T cell activation.
    Yan R; Yang S; Gu A; Zhan F; He C; Qin C; Zhang X; Feng P
    Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):395-8. PubMed ID: 24328742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-h3 and its role in antitumor immunity.
    Loos M; Hedderich DM; Friess H; Kleeff J
    Clin Dev Immunol; 2010; 2010():683875. PubMed ID: 21127709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.
    Leitner J; Klauser C; Pickl WF; Stöckl J; Majdic O; Bardet AF; Kreil DP; Dong C; Yamazaki T; Zlabinger G; Pfistershammer K; Steinberger P
    Eur J Immunol; 2009 Jul; 39(7):1754-64. PubMed ID: 19544488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.
    Xu H; Cheung IY; Guo HF; Cheung NK
    Cancer Res; 2009 Aug; 69(15):6275-81. PubMed ID: 19584290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
    Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
    Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3 in Cancer - Beyond Immune Regulation.
    Flem-Karlsen K; Fodstad Ø; Tan M; Nunes-Xavier CE
    Trends Cancer; 2018 Jun; 4(6):401-404. PubMed ID: 29860983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.
    Calabrò L; Sigalotti L; Fonsatti E; Bertocci E; Di Giacomo AM; Danielli R; Cutaia O; Colizzi F; Covre A; Mutti L; Natali PG; Maio M
    J Cell Physiol; 2011 Oct; 226(10):2595-600. PubMed ID: 21792917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
    Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
    FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Identification and characterization of monoclonal antibody Y4F11 against human B7-H3].
    Shi Z; Hu Y; Chen H; Fu F; Zhang X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Oct; 32(10):1402-1406. PubMed ID: 27667469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
    Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
    Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer.
    Han S; Wang Y; Shi X; Zong L; Liu L; Zhang J; Qian Q; Jin J; Ma Y; Cui B; Yang X; Kong B; Zhang Y
    Exp Cell Res; 2018 Oct; 371(1):222-230. PubMed ID: 30099052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells.
    Shao L; Yu Q; Xia R; Zhang J; Gu S; Yu D; Zhuang Z
    Pathol Res Pract; 2021 Aug; 224():153461. PubMed ID: 34265738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice.
    Yin SJ; Wang WJ; Zhang JY
    Genet Mol Res; 2015 Nov; 14(4):14253-61. PubMed ID: 26600483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.